SCHEMBL12584522

SCHEMBL12584522

O=C(Cc1cc(I)c(Oc2cc(I)c(OCC3CO3)c(I)c2)c(I)c1)O/C(=N/C1CCCCC1)NC1CCCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ THRB P10828 5/20 0.35
▸ THRA P10827 4/20 0.35
▸ PPARG P37231 4/20 0.35
▸ RXRA P19793 3/20 0.35
▸ ITGB3 P05106 1/20 0.35
▸ ITGAV P06756 1/20 0.35
▸ PCNA P12004 4/20 0.33
▸ MEN1 O00255 5/20 0.32
▸ KMT2A Q03164 5/20 0.32
▸ LMNA P02545 3/20 0.32
▸ ADORA3 P0DMS8 3/20 0.32
▸ PDE4D Q08499 3/20 0.32
▸ HSD17B10 Q99714 3/20 0.32
▸ TTR P02766 2/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ HTR1A P08908 2/20 0.32
▸ CYP2C9 P11712 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19696711 0.95 THRB (0.34) SMN1; SMN2NPC1RAB9ATHRBTHRA
SCHEMBL12584523 0.87 THRB (0.36) SMN1; SMN2THRBTHRAPPARGRXRA
SCHEMBL1525943 0.85 EPHX2 (0.42) SMN1; SMN2NPC1RAB9ATHRBTHRA
SCHEMBL19696689 0.84 THRB (0.35) THRBTHRAPPARGRXRAITGB3
SCHEMBL15942568 0.81 — —
SCHEMBL12837222 0.80 EPHX2 (0.42) SMN1; SMN2NPC1RAB9ATHRBTHRA
SCHEMBL1525949 0.77 MGLL (0.46) SMN1; SMN2THRBTHRAPPARGRXRA
SCHEMBL1526072 0.75 THRB (0.61) SMN1; SMN2THRBTHRAPPARGRXRA
SCHEMBL14239796 0.72 MGLL (0.43) SMN1; SMN2THRBTHRAPPARGRXRA
SCHEMBL1525910 0.71 THRB (0.43) SMN1; SMN2THRBTHRAPPARGRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9839614-B2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof NANOPHARMACEUTICALS, LLC (US) 2017-12-12 — — US disclosed
US-9839614-B2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof NANOPHARMACEUTICALS, LLC (US) 2017-12-12 — — US disclosed
US-20160199309-A1 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF NANOPHARMACEUTICALS, LLC 2016-07-14 — — US disclosed
US-20160199309-A1 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF NANOPHARMACEUTICALS, LLC 2016-07-14 — — US disclosed
US-9289395-B2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof NANOPHARMACEUTICALS LLC (US) 2016-03-22 — — US disclosed
US-9289395-B2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof NANOPHARMACEUTICALS LLC (US) 2016-03-22 — — US disclosed
US-9220788-B2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof NANOPHARMACEUTICALS LLC (US) 2015-12-29 — — US disclosed
US-9220788-B2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof NANOPHARMACEUTICALS LLC (US) 2015-12-29 — — US disclosed
US-20110142941-A1 Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof NANOPHARMACEUTICALS LLC 2011-06-16 — — US disclosed
US-20110142941-A1 Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof NANOPHARMACEUTICALS LLC 2011-06-16 — — US disclosed
US-20090022806-A1 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof ORDWAY RESEARCH INSTITUTE, INC. 2009-01-22 — — US disclosed
US-20090022806-A1 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof ORDWAY RESEARCH INSTITUTE, INC. 2009-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090022806-A1 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof TSHR, THRA, TRHR SMN1; SMN2 4865/4885NPC1 3531/4885RAB9A 1521/4885
US-20160199309-A1 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF TSHR, THRA, TRHR SMN1; SMN2 4864/4885NPC1 3347/4885RAB9A 1397/4885
US-20110142941-A1 Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof TSHR, THRA, TRHR SMN1; SMN2 4868/4885NPC1 3389/4885RAB9A 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback